FDA orders blindness-risk warning on GLP-1 obesity drugs

· Finance · United States

The US Food and Drug Administration ordered a warning about blindness risk on obesity drugs, citing an increased risk of a rare eye condition that can cause permanent vision loss in users of GLP-1 medicines. The label change affects a fast-growing class of weight-loss and diabetes treatments that has become one of the industry's biggest revenue drivers. The rare condition is non-arteritic anterior ischemic optic neuropathy, a condition linked in earlier studies to these drugs. The agency's action sets new disclosure requirements for makers of the medicines and could influence prescribing and patient discussions.

Why it matters：GLP-1 drugs are among the industry's biggest growth franchises, so a mandated safety warning affects labeling, prescribing and the competitive positioning of every maker in the class.

Key points

  • The warning concerns a rare eye condition that can cause permanent vision loss.
  • The FDA action applies to users of GLP-1 medicines.
  • The step adds new disclosure requirements for drugmakers in the class.

Sources (original reporting)

More stories from this day